Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations

Archives of Neurology

Volumn 61, Issue 6, 2004, Pages 865-868

  O'Suilleabhain, Padraig E ^a   Sung, Victor ^a   Hernandez, Carlos ^a   Lacritz, Laura ^a   Dewey Jr , Richard B ^a   Bottiglieri, Teodoro ^b   Diaz Arrastia, Ramon ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; PARKINSON DISEASE; PHYSICAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; RISK ASSESSMENT; RISK FACTOR; TASK PERFORMANCE; VITAMIN BLOOD LEVEL;

AGED; COGNITION DISORDERS; DEPRESSION; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES;

EID: 2942525889     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.6.865     Document Type: Article

References (30)

1. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
2. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987;37:226-232.
3. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
4. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam Study. J Intern Med. 1997;242:339-347.
5. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131:352-355.
6. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N EnglJ Med. 2002;346:476-483.
7. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003;126(pt 1):170-175.
8. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002;59:1375-1380.
9. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson's disease. J Neurol. 1998;245:811-812.
10. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999;354:126-127.
11. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K, Plasma homocysteine and MTHFR G677T genotype in levodopa-treated patients with PD. Neurology. 2000;55:437-440.
12. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and I-dopa metabolism in patients with Parkinson disease. Clin Chem. 2001;47:1102-1104.
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
14. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
15. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441-446.
16. Gamache P, Ryan E, Svendsen C, Murayama K, Acworth IN. Simultaneous measurement of monoamines, metabolites and amino acids in brain tissue and microdialysis perfusates. J Chromatogr. 1993;614:213-220.
17. Beck AT, Steer RA, Brown GK. BDI-II Manual. San Antonio, Tex: Psychological Corp; 1996.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
19. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY: Oxford University Press Inc; 1991.
20. Trenerry MR, Crosson B, DeBoe J, Leber WR. The Stroop Neuropsychological Screening Test. Odessa, Fla: Psychological Assessment Resources; 1989.
21. Wechsler O. Wechsler Adult Intelligence Scale-Third Edition: Administration and Scoring Manual. San Antonio, Tex: Psychological Corp; 1997.
22. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43-55.
23. Corwin J, Bylsma FW. Translations of excerpts from Andre Rey's "Psychological Examination of Traumatic Encephalapathy" and P.A. Osterrieth's "The Complex Figure Copy Test." Clin Neuropsychol. 1993;7:3-21.
24. Fahn S, Elton SR. Unified Parkinson's Disease Rating Scale. In: Fahn S, et al, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-164.
25. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol. 2003;60:59-64.
26. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of I-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997; 20:55-66.
27. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand. 2003;108:66-67.
28. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:5923-5928.
29. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002;80:101-110.
30. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.